aTyr Pharma (LIFE) : Traders are bullish on aTyr Pharma (LIFE) as it has outperformed the S&P 500 by a wide margin of 12.22% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 17.66%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.59% in the last 1 week, and is up 15.99% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 20.62% and the 50-Day Moving Average is 14.54%. aTyr Pharma Inc. has dropped 4.21% during the last 3-month period . Year-to-Date the stock performance stands at -65.31%.
aTyr Pharma (NASDAQ:LIFE): stock turned positive on Friday. Though the stock opened at $2.97, the bulls momentum made the stock top out at $3.43 level for the day. The stock recorded a low of $2.911 and closed the trading day at $3.41, in the green by 14.81%. The total traded volume for the day was 1,430,526. The stock had closed at $2.97 in the previous days trading.
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines, a class of naturally occurring proteins that promotes homeostasis. The Companys Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction, including severe diseases of the lung, gut, skin, brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue, an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.